Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Get this document free

ReportsnReports.com - Global Clinical Trials Market (2007 - 2010)

VIEWS: 43 PAGES: 12

The global clinical trials conducted in 2008 were reported to be 10,326 and were highest from 2007 to 2010. Oncology trials were the most widely conducted clinical trials accounting for 28.47% of all the trials conducted for the year 2008. Asia reported to a steady growth as compared to the other regions; which showed decline in the total number of clinical trials in the year 2010.

More Info
									Global Clinical Trials Market (2007 - 2010)
Published: September 2011
Price: $ 4650




Clinical trials market now witnesses a paradigm shift. Naïve heterogeneous patient
populations in the developing nations are opening up new avenues for the clinical trials
market. Developing countries also offer faster means; which is triggering major
pharmaceutical companies to direct their investment in these regions. Apart from this,
stringent regulations and tight R&D budgets in the pharma-biotech industry are also
forcing companies to move to east. This scenario has further boosted the alliances
between the pharma-biotech companies and the clinical research organizations, with the
latter accounting for major chunk of the trials conducted.

Today, emerging countries account for the largest share of the phase II/III (prime stages)
clinical trials conducted globally with major focus on oncology, Alzheimer’s, metabolic, and
cardiovascular diseases. Support from the respective government bodies is one of the
major factors affecting the clinical trials market. Clinical trials sponsored by the industry
have a much higher share in the market as compared to government organizations.

Browse All: Pharmaceuticals Market Research


North America includes the U.S. and Canada; together both the countries have reported to
have the largest number of clinical trials conducted globally. In the European region,
Germany heads the largest number of clinical trials, the country was reported to have
conducted 734 trials for 2010 in Western Europe while Poland accounted for the largest
number of clinical trials in Eastern Europe with total number of 263 clinical trials for 2010.

Asia is one of the fastest growing markets for global clinical trials. The countries taking lead
in this market are India, China, South Korea, and Singapore. The major reasons for this
market to have high potential are its huge and diverse population with diseases that are
present in both - the developed and under developed countries. Hence, different types of
trials can be conducted in one region. Due to large population, it helps in faster recruitment
of the patients, and retention of the participants in the trials on the higher side; thereby
helping the companies to conduct the trials on the timely basis.

The financial targets and global competition are forcing the pharmaceutical players to look
out for various options to introduce novel therapies in the market. At the same time,
emerging shortage of clinical resources such as lack of naïve disease population, well
trained labor, and sound medical infrastructure are delaying the process to initiate trials.
Hence, all these companies are considering Latin America as an alternative option for
conducting clinical trials.
The key players (Clinical Research Organizations) in the market include Chiltern, Omnicare,
PPD, Parexel, Kendle, and Quintles.

The global clinical trials conducted in 2008 were reported to be 10,326 and were highest
from 2007 to 2010. Oncology trials were the most widely conducted clinical trials
accounting for 28.47% of all the trials conducted for the year 2008. Asia reported to a
steady growth as compared to the other regions; which showed decline in the total number
of clinical trials in the year 2010.

Scope of the report

Global clinical trials market research report categorizes by phases, by the study design, by
the disease indications and with analysis of the geographic trends of conducting the clinical
trials.

Clinical trials market by phases:

   Phase I
   Phase II
   Phase III
Clinical trials market by study design

   Interventional trials
   Observational trials
   Expanded Access trials.
Clinical trials market by indications

   Autoimmune
   Blood disorders
   Cancer
   Circulatory
   CNS
   Congenital
   CVS
   Dermatology
   Ear
   Gastrointestinal
   Genitourinary
   Infections
   Mental disorders
   Metabolic
   Musculoskeletal
   Nose
   Ophthalmology
   Others
Clinical trials on basis of geography:

   North America
   South America
   Asia
   Europe
Each section of the report provides market tables for covering the number of clinical trials
conducted between 2007 and 2010.

In addition, the report also provides 19 company profiles of the CROs covering the services
and geographic presence.

TABLE OF CONTENTS

1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY

2 EXECUTIVE SUMMARY
2.1 OVERVIEW OF THE MARKET
2.2 KEY FINDINGS

3 MARKET OVERVIEW
3.1 MARKET DEFINITION
3.2 DRIVERS
3.2.1 GLOBALIZING DRUG DEVELOPMENT ACTIVITIES
3.2.2 RISE IN R&D INVESTMENTS EXPECTED TO BOOST THE CLINICAL TRIALS MARKET
3.2.3 HIGH DISEASE PREVALENCE IN EMERGING COUNTRIES
3.3 RESTRAINTS
3.3.1 LONGER APPROVAL TIME FOR CLINICAL TRIALS – A CAUSE OF CONCERN FOR MAJOR
PHARMACEUTICAL-BIOTECHNOLOGY PLAYERS
3.4 BURNING ISSUES
3.4.1 OUT SKIRTING BOUNDARIES OF MEDICAL ETHICS
3.5 WINNING IMPERATIVES
3.5.1 LEVERAGING ONLINE RESOURCES TO INCREASE PATIENT RECRUITMENT RATES IN
CLINICAL TRIALS
3.6 COUNTRY COMPARISON
3.7 INDUSTRY TRENDS
3.7.1 ENGAGING CLINICAL TRIALS IN EMERGING COUNTRIES & LOW COST CRO’S PROVE
TO BE COMPELLING OPTIONS IN TIMES OF DRUG PATENT EXPIRY
3.7.2 CROS LEVERAGING THE BENEFITS OF EMERGING MARKETS
3.7.3 CHANGING CRO BUSINESS MODELS
3.7.3.1 Full service model
3.7.3.2 Hourly billing model
3.7.3.3 Full time equivalent model (FTE)
3.7.3.4 Fixed price model
3.7.4 PREVALENCE OF PREFERRED PROVIDER RELATIONSHIPS
3.7.5 SHIFT TOWARDS PATIENT CENTRIC CLINICAL TRIALS DUE TO TECHNICAL
ADVANCES
3.8 GLOBAL CLINICAL TRIALS MARKET
3.8.1 OFFSHORING & OUTSOURCING

4 CLINICAL TRIALS MARKET, BY TYPES
4.1 INTRODUCTION
4.1.1 CLINICAL TRIALS MARKET, BY STUDY PHASES
4.1.1.1 Preclinical studies
4.1.1.2 Phase I trials
4.1.1.3 Phase II trials
4.1.1.4 Phase I/II
4.1.1.5 Phase II/III
4.1.1.6 Phase III trials
4.1.2 CLINICAL TRIALS MARKET, BY STUDY DESIGNS
4.1.2.1 Observational studies
4.1.2.2 Interventional studies
4.1.2.3 Expanded Access Trials
4.1.3 CLINICAL TRIALS MARKET, BY INDICATIONS

5 GEOGRAPHIC ANALYSIS
5.1 NORTH AMERICA
5.1.1 U.S.
5.1.1.1 Regulatory environment
5.1.1.2 Clinical trials registry
5.1.1.3 Government support
5.1.2 CANADA
5.1.2.1 Regulatory environment
5.1.2.2 Clinical trials registry
5.1.2.3 Government support
5.2 EUROPE
5.2.1 UK
5.2.1.1 Regulatory environment
5.2.1.2 Clinical trials registry
5.2.1.3 Government support
5.2.2 GERMANY
5.2.2.1 Regulatory environment
5.2.2.2 Clinical trials registry
5.2.2.3 Government support
5.2.3 ITALY
5.2.3.1 Regulatory environment
5.2.3.2 Clinical trials registry
5.2.3.3 Government support
5.2.4 FRANCE
5.2.4.1 Regulatory environment
5.2.4.2 Clinical trials registry
5.2.4.3 Support rendered by the    government
5.2.5 SPAIN
5.2.5.1 Regulatory environment
5.2.5.2 Clinical trials registry
5.2.5.3 Government support
5.2.6 POLAND
5.2.6.1 Regulatory environment
5.2.6.2 Clinical trials registry
5.2.6.3 Support rendered by the    Government
5.2.7 RUSSIA
5.2.7.1 Regulatory environment
5.2.7.2 Clinical trials registry
5.2.7.3 Support rendered by the    Government
5.2.8 TURKEY
5.2.8.1 Regulatory environment
5.2.8.2 Clinical trials registry
5.2.8.3 Government support
5.2.9 UKRAINE
5.2.9.1 Regulatory environment
5.2.9.2 Clinical trials registry
5.2.9.3 Support rendered by the    Government
5.3 ASIA
5.3.1 CHINA
5.3.1.1 Clinical trials registry
5.3.1.2 Government support
5.3.2 INDIA
5.3.2.1 Regulatory environment
5.3.2.2 Clinical trials registry
5.3.2.3 Government support
5.3.3 SOUTH KOREA
5.3.3.1 Regulatory environment
5.3.3.2 Clinical trials registry
5.3.3.3 Government support
5.4 LATIN AMERICA
5.4.1 BRAZIL
5.4.1.1 Regulatory environment
5.4.1.2 Clinical trials registry
5.4.1.3 Government support
5.4.2 MEXICO
5.4.2.1 Regulatory environment
5.4.2.2 Clinical trials registry
5.4.2.3 Government support
5.4.3 ARGENTINA
5.4.3.1 Regulatory environment
5.4.3.2 Clinical trials registry
5.4.3.3 Government support

6 COMPETITIVE LANDSCAPE
6.1 INTRODUCTION

7 COMPANY PROFILES
7.1 AAIPHARMA SERVICES CORP.
7.1.1 OVERVIEW
7.1.2 FINANCIALS
7.1.3 PRODUCTS & SERVICES
7.1.4 STRATEGY
7.1.5 DEVELOPMENTS
7.2 ACCELL CLINICAL RESEARCH LLC
7.2.1 OVERVIEW
7.2.2 FINANCIALS
7.2.3 PRODUCTS & SERVICES
7.2.4 STRATEGY
7.2.5 DEVELOPMENTS
7.3 APTIV SOLUTIONS
7.3.1 OVERVIEW
7.3.2 FINANCIALS
7.3.3 PRODUCTS & SERVICES
7.3.4 STRATEGY
7.3.5 DEVELOPMENTS
7.4 CHILTERN INTERNATIONAL LIMITED
7.4.1 OVERVIEW
7.4.2 FINANCIALS
7.4.3 PRODUCTS & SERVICES
7.4.4 STRATEGY
7.4.5 DEVELOPMENTS
7.5 CONGENIX
7.5.1 OVERVIEW
7.5.2 FINANCIALS
7.5.3 PRODUCTS & SERVICES
7.5.4 STRATEGY
7.5.5 DEVELOPMENTS
7.6 COVANCE INC.
7.6.1 OVERVIEW
7.6.2 FINANCIALS
7.6.3 PRODUCTS & SERVICES
7.6.4 STRATEGY
7.6.5 DEVELOPMENTS
7.7 ECRON ACUNOVA LTD
7.7.1 OVERVIEW
7.7.2 FINANCIALS
7.7.3 PRODUCTS & SERVICES
7.7.4 STRATEGY
7.7.5 DEVELOPMENTS
7.8 EUROTRIALS
7.8.1 OVERVIEW
7.8.2 FINANCIALS
7.8.3 PRODUCTS & SERVICES
7.8.4 DEVELOPMENTS
7.9 ICON PLC
7.9.1 OVERVIEW
7.9.2 FINANCIALS
7.9.3 PRODUCTS & SERVICES
7.9.4 STRATEGY
7.9.5 DEVELOPMENTS
7.10 INC RESEARCH LLC
7.10.1 OVERVIEW
7.10.2 FINANCIALS
7.10.3 PRODUCTS & SERVICES
7.10.4 STRATEGY
7.10.5 DEVELOPMENTS
7.11 MEDPACE INC
7.11.1 OVERVIEW
7.11.2 FINANCIALS
7.11.3 PRODUCTS & SERVICES
7.11.4 STRATEGY
7.11.5 DEVELOPMENTS
7.12 PAREXEL INTERNATIONAL CORP
7.12.1 OVERVIEW
7.12.2 FINANCIALS
7.12.3 PRODUCTS & SERVICES
7.12.4 STRATEGY
7.12.5 DEVELOPMENTS
7.13 PHARMANET DEVELOPMENT GROUP
7.13.1 OVERVIEW
7.13.2 FINANCIALS
7.13.3 PRODUCTS & SERVICES
7.13.4 STRATEGY
7.13.5 DEVELOPMENTS
7.14 PHARMACEUTICAL PRODUCT DEVELOPMENT INC
7.14.1 OVERVIEW
7.14.2 FINANCIALS
7.14.3 PRODUCTS & SERVICES
7.14.4 STRATEGY
7.14.5 DEVELOPMENTS
7.15 PRA INTERNATIONAL
7.15.1 OVERVIEW
7.15.2 FINANCIALS
7.15.3 PRODUCTS & SERVICES
7.15.4 STRATEGY
7.15.5 DEVELOPMENTS
7.16 QUINTILES TRANSNATIONAL CORP
7.16.1 OVERVIEW
7.16.2 FINANCIALS
7.16.3 PRODUCTS & SERVICES
7.16.4 STRATEGY
7.16.5 DEVELOPMENTS
7.17 SIRO CLINPHARM PVT. LTD
7.17.1 OVERVIEW
7.17.2 FINANCIALS
7.17.3 PRODUCTS & SERVICES
7.17.4 STRATEGY
7.17.5 DEVELOPMENTS
7.18 TCG LIFESCIENCES LTD
7.18.1 OVERVIEW
7.18.2 FINANCIALS
7.18.3 PRODUCTS & SERVICES
7.18.4 STRATEGY
7.18.5 DEVELOPMENTS
7.19 THEOREM CLINICAL RESEARCH
7.19.1 OVERVIEW
7.19.2 FINANCIALS
7.19.3 PRODUCTS & SERVICES
7.19.4 STRATEGY
7.19.5 DEVELOPMENTS

LIST OFTABLES

TABLE 1GLOBAL CLINICAL TRIALS, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 2CLINICAL TRIALS APPROVAL: TIME & AUTHORITY
TABLE 3DRUGS SET FOR PATENT EXPIRATIONS, 2010–2012
TABLE 4PHASE I CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 – 2010 (NO. OF TRIALS)
TABLE 5GLOBAL PHASE I CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO.
OF TRIALS)
TABLE 6PHASE II CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 – 2010 (NO. OF
TRIALS)
TABLE 7GLOBAL PHASE II CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO.
OF TRIALS)
TABLE 8PHASE I/II CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 – 2010 (NO. OF
TRIALS)
TABLE 9GLOBAL PHASE I/II CLINICAL TRIALS, BY INDICATIONS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 10 PHASE II/III CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 – 2010 (NO. OF
TRIALS)
TABLE 11 GLOBAL PHASE II/III CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010
(NO. OF TRIALS)
TABLE 12 PHASE III CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 – 2010 (NO. OF
TRIALS)
TABLE 13 GLOBAL PHASE III CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010
(NO. OF TRIALS)
TABLE 14 OBSERVATIONAL STUDIES: CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 –
2010 (NO. OF TRIALS)
TABLE 15 INTERVENTIONAL STUDIES: CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 –
2010 (NO. OF TRIALS)
TABLE 16 EXPANDED ACCESS: CLINICAL TRIALS, BY GEOGRAPHY, 2007 – 2010 (NO. OF
TRIALS)
TABLE 17 GLOBAL CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 18 NORTH AMERICA: CLINICAL TRIALS MARKET, BY COUNTRIES, 2007 – 2010 (NO.
OF TRIALS)
TABLE 19 U.S: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 20 U.S: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 21 U.S: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 22 CANCER FUNDING IN THE U.S., BY TYPES, 2008 – 2010 ($MILLION)
TABLE 23 CANADA: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 24 CANADA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 25 CANADA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 26 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRIES, 2007 – 2010 (NO. OF
TRIALS)
TABLE 27 UK: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 28 UK: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 29 UK: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 30 GERMANY: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 31 GERMANY: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 32 GERMANY: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 33 ITALY: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 34 ITALY: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 35 ITALY: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 36 FRANCE: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 37 FRANCE: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 38 FRANCE: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 39 SPAIN: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 40 SPAIN: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 41 SPAIN: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 42 POLAND: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 43 POLAND: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 44 POLAND: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 45 RUSSIA: CLINICAL TRIALS MARKET BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 46 RUSSIA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 47 RUSSIA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 48 TURKEY: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 49 TURKEY: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 50 TURKEY: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 51 UKRAINE: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 52 UKRAINE: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 53 UKRAINE: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 54 ASIA: CLINICAL TRIALS MARKET, BY COUNTRY, 2007 – 2010 (NO. OF TRIALS)
TABLE 55 CHINA: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 56 CHINA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 57 CHINA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 58 INDIA: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 59 INDIA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 60 INDIA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 61 SOUTH KOREA: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF
TRIALS)
TABLE 62 SOUTH KOREA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010
(NO. OF TRIALS)
TABLE 63 SOUTH KOREA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO.
OF TRIALS)
TABLE 64 LATIN AMERICA: CLINICAL TRIALS MARKET, BY COUNTRY, 2007 – 2010 (NO. OF
TRIALS)
TABLE 65 BRAZIL: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 66 BRAZIL: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 67 BRAZIL: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 68 MEXICO: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 69 MEXICO: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 70 MEXICO: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 71 ARGENTINA: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF
TRIALS)
TABLE 72 ARGENTINA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO.
OF TRIALS)
TABLE 73 ARGENTINA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF
TRIALS)
TABLE 74 NEW APPROVALS, 2008 – 2010
TABLE 75 EXPANSIONS, 2008 – 2011
TABLE 76 NEW TRIALS, 2007 – 2011
TABLE 77 COLLABORATIONS & PARTNERSHIPS, 2008 – 2011
TABLE 78 MERGERS & ACQUISITIONS, 2007 – 2011
TABLE 79 CHILTERN: TOTAL REVENUE, 2008 – 2010 ($MILLION)
TABLE 80 COVANCE INC: TOTAL REVENUE, 2008 – 2010 ($MILLION)
TABLE 81 COVANCE INC.: TOTAL REVENUE, BY COUNTRY, 2008 – 2010 ($MILLION)
TABLE 82 COVANCE INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 83 ICON PLC: TOTAL REVENUE, 2008 – 2010 ($MILLION)
TABLE 84 ICON PLC: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 85 ICON PLC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 86 PAREXEL INTERNATIONAL CORPORATION: TOTAL REVENUE, BY GEOGRAPHY,
2008 – 2010 ($MILLION)
TABLE 87 PAREXEL INTERNATIONAL CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2008
– 2010 ($MILLION)
TABLE 88 PHARMACEUTICAL PRODUCT DEVELOPMENT INC: TOTAL REVENUE, 2008 – 2010
($MILLION)
TABLE 89 PHARMACEUTICAL PRODUCT DEVELOPMENT INC: TOTAL REVENUE, BY COUNTRY,
2008 – 2010 ($MILLION)
TABLE 90 PHARMACEUTICAL PRODUCT DEVELOPMENT INC: TOTAL REVENUE, BY
SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 91 THEOREM CLINICAL RESEARCH: TOTAL REVENUE, 2008 – 2010 ($MILLION)
TABLE 92 THEOREM CLINICAL RESEARCH: TOTAL REVENUE, BY COUNTRY, 2008 – 2010
($MILLION)
TABLE 93 THEOREM CLINICAL RESEARCH: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010
($MILLION)

LIST OFFIGURES

FIGURE 1COUNTRY WISE PARAMETRIC COMPARISON
FIGURE 2COST OF CLINICAL TRIALS, BY COUNTRY
FIGURE 3U.S: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 4CANADA: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 5UK: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 6GERMANY: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 7ITALY: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 8FRANCE: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 9SPAIN: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 10 POLAND: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 11 RUSSIA: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 12 TURKEY: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 13 UKRAINE: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 14 CHINA: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 15 INDIA: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 16 SOUTH KOREA: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 17 BRAZIL: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 18 MEXICO: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 19 ARGENTINA: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 20 MAJOR GROWTH STRATEGIES IN GLOBAL CLINICAL TRIALS MARKET, JANUARY
2008 – JULY 2011


About Us:
ReportsnReports is an online library of over 100,000+ market research reports and in-depth
market research studies & analysis of over 5000 micro markets. We provide 24/7 online and
offline support to our customers. Get in touch with us for your needs of market research
reports.

Follow us on Twitter: http://twitter.com/marketsreports

Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: + 1 888 391 5441

E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit our Market Research Blog

								
To top